Dr Tamara Milder

Dr Tamara Milder

Research Associate

Bachelor of Medicine Bachelor of Surgery Honours Class 1, UNSW Sydney (2011)

Fellow of the Royal Australasian College of Physicians (Adult Medicine Division - specialist endocrinologist) (2018)

Master of Medicine (Clinical Epidemiology), University of Sydney (2019)

 

Medicine & Health
School of Population Health

I graduated with a Bachelor of Medicine Bachelor of Surgery with Honours Class 1 in 2011 from UNSW Sydney. I obtained a Fellowship of the Royal Australasian College of Physicians as a specialist endocrinologist in 2018. I work as an endocrinologist in St Vincent's Clinic. I have a Master of Medicine (Clinical Epidemiology) from the University of Sydney (2019). I am finishing a PhD through the Garvan Institute of Medical Research, UNSW about the effective and safe use of sodium-glucose cotransporter 2 inhibitors. I am a Research Associate in the Medicines Intelligence Research Program in the School of Population Health, UNSW Sydney. 

Location
Samuels Building (F25)
  • Journal articles | 2024
    Kam PCA; Milder TY; Milder DA, 2024, 'Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists: a reply', Anaesthesia, 79, pp. 1133, http://dx.doi.org/10.1111/anae.16369
    Journal articles | 2024
    Milder DA; Milder TY; Liang SS; Kam PCA, 2024, 'Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice', Anaesthesia, 79, pp. 735 - 747, http://dx.doi.org/10.1111/anae.16306
    Journal articles | 2024
    Milder TY; Lin J; Pearson SA; Greenfield JR; Day RO; Stocker SL; Neuen BL; Falster MO; de Oliveira Costa J, 2024, 'Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.16231
    Journal articles | 2024
    de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes, Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597
    Journal articles | 2023
    Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068
    Journal articles | 2023
    Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5
    Journal articles | 2023
    Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2023, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16203
    Journal articles | 2022
    Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97, http://dx.doi.org/10.1016/j.hlc.2022.06.117
    Journal articles | 2022
    Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727
    Journal articles | 2021
    Milder T; Stocker S; Baysari M; Day RO; Greenfield J, 2021, 'Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', DIABETES, 70, http://dx.doi.org/10.2337/db21-779-P
    Journal articles | 2021
    Milder TY; Stocker SL; Baysari M; Day RO; Greenfield JR, 2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, 180, http://dx.doi.org/10.1016/j.diabres.2021.109036
    Journal articles | 2020
    Milder TY; Day RO; Stocker SL; Greenfield JR, 2020, 'Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes', Internal Medicine Journal, 50, pp. 645 - 646, http://dx.doi.org/10.1111/imj.14819
    Journal articles | 2020
    Milder TY; Stocker SL; Day RO; Greenfield JR, 2020, 'Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease', Drug Safety, 43, pp. 1211 - 1221, http://dx.doi.org/10.1007/s40264-020-01010-6
    Journal articles | 2019
    Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR, 2019, 'Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease', European Journal of Clinical Pharmacology, 75, pp. 1481 - 1490, http://dx.doi.org/10.1007/s00228-019-02732-y
    Journal articles | 2019
    Milder TY; Stocker SL; Shaheed CA; McGrath-Cadell L; Samocha-Bonet D; Greenfield JR; Day RO, 2019, 'Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis', JOURNAL OF CLINICAL MEDICINE, 8, http://dx.doi.org/10.3390/jcm8010045
    Journal articles | 2019
    2019, 'Book review: Therapeutic Guidelines: Diabetes. Version 1', Australian Prescriber, 42, pp. 205 - 205, http://dx.doi.org/10.18773/austprescr.2019.063
    Journal articles | 2018
    Milder DA; Milder TY; Kam PCA, 2018, 'Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations', Anaesthesia, 73, pp. 1008 - 1018, http://dx.doi.org/10.1111/anae.14251
    Journal articles | 2011
    Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514
  • Conference Abstracts | 2017
    Milder TY; Greenfield J; Matthews G; Center J, 2017, 'Hypophosphataemic osteomalacia induced by tenofovir disoproxil fumarate', in CLINICAL ENDOCRINOLOGY, WILEY, AUSTRALIA, Perth, Vol. 89, pp. 70 - 70, presented at Joint Annual Scientific Meetings of Endocrine-Society-of-Australia (ESA) and Society-for-Reproductive-Biology (SRB), AUSTRALIA, Perth, 27 August 2017 - 30 August 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000436537900157&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Collaborative Grant, $30,000

2023 UNSW Cardiac, Vascular and Metabolic Medicine Theme Symposium Best Oral Presentation

As an endocrinologist, I have a strong clinical and academic interest and expertise in diabetes pharmacotherapy, specifically medicines with major cardiac and renal benefits - sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). I have explored the implementation of SGLT2i through a mixed-methodology approach, having both undertaken novel qualitative and pharmacoepidemiology studies. As a member of the Medicines Intelligence Research Program, I have explored the uptake of SGLT2i and GLP-1 RA in people with type 2 diabetes in New South Wales and Australia. These projects have shown a considerable underutilisation of these cardiorenal medicines, as well as geographic variation in their use. We are expanding our implementation studies about these medicines.

I also have an interest in the perioperative management of people using SGLT2i and GLP-1 RA, and have published reviews and works on this subject.